Peritoneal dialysis efficiency in CAPD patients in treatment with rHuEPO.
Possible modifications in peritoneal behaviour that can be caused by erythropoietin (EPO) treatment and/or correction of anemia in the ultrafiltration and peritoneal diffusion were studied in 24 CAPD patients. The evolution of the patients on the medium run was also studied. The dialysate to plasma ratio, the peritoneal clearance and the mass transfer coefficient of urea and creatinine and the ultrafiltration volume were studied, baseline, after reaching the hemoglobin target, and after eight months of treatment. The group of patients developed a decrease in the dialysate to plasma ratio and in the peritoneal clearance of creatinine. After evaluating the effects of the hemoglobin and the hematocrit, we found a decrease in the dialysate to plasma ratio of urea and creatinine, and in the peritoneal clearance of creatinine. A decrease was also found in the mass transfer coefficients of urea and creatinine. An increase in the ultrafiltration was also found in the patients with hemoglobin levels higher or equal to 11 g/dl. Those changes are reversible after turning the hemoglobin levels back to levels lower than 11 g/dl.
Vega
N
N
Hospital Ntra. Sra. del Pino, Las Palmas de Gran Canaria, Canary Islands, Spain.
Fernandez
A
A
Hortal
L
L
Macias
M
M
Rodriguez
J C
JC
Plaza
C
C
Perdomo
M
M
Vega
R
R
Palop
L
L
D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy; D003404:Creatinine / Q000378:metabolism; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000378:metabolism*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014508:Urea / Q000378:metabolism
D011994:Recombinant Proteins; D004921:Erythropoietin; D014508:Urea; D003404:Creatinine